Abstract: A method and apparatus for maintaining the airworthiness configuration of an aircraft. Airworthiness configuration information for an aircraft is identified by a data processing system. The airworthiness configuration information identifies an airworthiness configuration of the aircraft comprising a number of components of the aircraft. A number of automated identification technology devices are attached to the aircraft. The number of automated identification technology devices include component information for the number of components. The component information is read from the number of automated identification technology devices by a reader. The component information read from the number of automated identification technology devices is compared, by a processor unit, to the airworthiness configuration information to determine whether the aircraft complies with the airworthiness configuration.

Abstract: Method and apparatus for managing equipment on an aircraft. An apparatus comprises an interrogator, a display system, and a processor unit. The interrogator is configured to read information from a set of wireless tags associated with a set of equipment in an aircraft. The processor unit is configured to identify the set of equipment from the information read from the set of wireless tags by the interrogator. The processor unit is further configured to display a layout of an interior of the aircraft on the display system. The processor unit is further configured to display a number of graphical indicators for the set of equipment on the layout in a number of locations on the layout corresponding to a number of locations of where the set of equipment is located in the interior of the aircraft.

Abstract: Methods for diagnosing and identifying genetic and metabolic factors associated with a physiologic procoagulant predisposition for and concurrent activation of the coagulation response in patients suffering from conditions such as chronic fatigue syndrome, fibromyalgia, Gulf War illness and cardiovascular disease are disclosed. Diagnostic assays utilized in the methods include measurement of blood levels of Protein C, Protein S, antithrombin, activated protein C resistance, prothrombin, plasminogen activator inhibitor-1, lipoprotein (a) and homocysteine. Treatment regimens include anticoagulant therapies comprising administering warfarin or heparin as needed.

Abstract: Disclosed is a method that includes steps of identifying conditions each associated with a low level activation of the coagulation response; conducting a clinical evaluation of a patient to determine a possibility that the patient has one of the conditions; if the clinical evaluation indicates the possibility that the patient has one of the conditions, providing a panel of different quantitative blood tests each capable of providing one of an abnormal result indicative of a low level activation of the coagulation response, and a normal result; performing the panel of different quantitative blood tests on the patient; obtaining a result for each of the blood tests; observing the results; and if at least two of the results are abnormal, using the abnormal results to assist in diagnosing the patient with the one of the conditions.

Abstract: This invention relates to a method for using a novel combination of assays to detect minimal activation of the coagulation response for determining whether a patient whose initial clinical evaluation indicates chronic fatigue syndrome, fibromyalgia, and related conditions can be treated using anticoagulant therapies. If activation of the coagulation response is detected, the present invention further includes treatment of CFS, FM or related condition using anticoagulant therapies.

Abstract: Methods for diagnosing and identifying genetic and metabolic factors associated with a physiologic procoagulant predisposition for and concurrent activation of the coagulation response in patients suffering from conditions such as chronic fatigue syndrome, fibromyalgia, Gulf War illness and cardiovascular disease are disclosed. Diagnostic assays utilized in the methods include measurement of blood levels of Protein C, Protein S, antithrombin, activated protein C resistance, prothrombin plasminogen activator inhibitor-1, lipoprotein (a) and homocysteine. Treatment regimens include anticoagulant therapies comprising administering warfarin or heparin as needed.